TITLE: Targeting HER2 and HER3 with Bispecific Antibodies in Breast Cancer
INVENTORS: Elizabeth S. Ward
TECHNOLOGY: Biologicals
UTSD: 2714
SUMMARY: The invention involves a novel bispecific antibody construct called TAb6 that
comprises a trastuuzumab full length antibody with single chain Fv fragments specific for HER3
linked to two CH3 domains of the antibody. We observed that in the presence of the HER3
stimulatory ligand, heregulin, that is frequently present in tumors, TAb6 combined with the small
molecule tyrosine inhibitor lapatinib is highly effective in reducing tumor cell proliferation; TAb6 is
more effective than either antibody alone or in combination. Thus, this bispecific antibody has
considerable potential for therapy, particularly given the low response rate in breast cancer
patients to trastuzumab.
Please contact the Office for Technology Development for more details:
Phone: 214-648-1816
Email: TechnologyDevelopment@utsouthwestern.edu
Please reference UT Southwestern Case Number: 2714